Xofyl 400 mg is a novel methylxanthine bronchodilator that differs structurally from theophylline by the inclusion of a dioxolane group at position 7. It selectively inhibits PDE-4, leading to bronchial smooth muscle relaxation. Reduced interaction with adenosine A₁ and A₂ receptors contributes to improved tolerability. Inhibition of PAF and leukotriene production further enhances its therapeutic effect.
100% Genuine Products, Guaranteed
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Xofyl 400 mg is a newer-generation bronchodilator that is structurally distinct from theophylline due to the presence of a dioxolane group at position 7. It exerts its bronchodilatory effect primarily through selective inhibition of phosphodiesterase-4 (PDE-4), leading to relaxation of bronchial smooth muscle.
Unlike theophylline, Xofyl demonstrates reduced affinity for adenosine A₁ and A₂ receptors, which may explain its comparatively improved safety and tolerability profile. Additionally, Xofyl has been reported to inhibit platelet-activating factor (PAF) and suppress leukotriene synthesis, contributing to its anti-inflammatory and bronchodilatory actions.
Overdose may result in serious adverse reactions, including:
These may be the initial signs of toxicity. Treatment should be discontinued if adverse effects occur and may be resumed at lower doses after symptoms resolve, at the physician’s discretion. There is no specific antidote; management is supportive and symptomatic, particularly in cases of cardiovascular compromise.
Adults:
400 mg tablet two to three times daily, or as directed by the physician
Elderly:
200 mg tablet two to three times daily
Children:
Above 12 years: 10 ml syrup or 200 mg tablet two to three times daily
6–12 years: 6–9 mg/kg body weight twice daily
Example: For a child weighing 10 kg, 3 ml (60 mg) twice daily
Dosage should be individualized based on patient response and clinical condition.
Xofyl 400 mg should not be used concurrently with other xanthine derivatives. Concomitant use with ephedrine may result in toxic synergistic effects.
As with other xanthines, drugs such as troleandomycin, lincomycin, clindamycin, allopurinol, cimetidine, ranitidine, propranolol, and influenza vaccines may reduce hepatic clearance, leading to increased plasma concentrations.
No clear correlation has been established between serum levels of Xofyl® and the occurrence of toxic effects.
Acute myocardial infarction
Patients with hypotension
Lactating women
Individuals with known hypersensitivity to any component of the formulation
Animal studies have shown no evidence of fetal harm or impaired reproductive capacity. However, due to limited data in humans, Xofyl 400 mg should be used during pregnancy only if clearly necessary.
Xofyl 400 mg is contraindicated during breastfeeding.
The elimination half-life of xanthine derivatives may be prolonged in patients with:
Concomitant use of drugs such as erythromycin, troleandomycin, lincomycin, allopurinol, cimetidine, propranolol, or influenza vaccines
Dose reduction may be required in these situations. Conversely, smoking and anticonvulsants (e.g., phenytoin) may increase drug clearance, necessitating higher doses.
Careful clinical monitoring is recommended during therapy.
Store in a cool, dry place away from light and heat. Keep out of reach of children.
Xofyl 400 mg should be used only on the prescription of a specialist physician.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.